Codexis, Inc. Overview
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million.
Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased)
Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases).
The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond.
Independent characterization
Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers.
The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products.
The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer.
The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain.
Value-chain position. Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company.
Customer types: large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell).
End-markets served: small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents.
Revenue model mix (FY2021–FY2025)
| Revenue type (USD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Product revenue | 70.7 | 116.7 | 42.9 | 36.8 | 26.0 |
| Research and development revenue | 34.1 | 21.9 | 27.2 | 22.6 | 44.4 |
| Total revenue | 104.8 | 138.6 | 70.1 | 59.3 | 70.4 |
| Product revenue share of total (%) | 67.5 | 84.2 | 61.2 | 62.0 | 37.0 |
| PAXLOVID-related enzyme sales (CDX-616) | 34.5 | 75.4 | 8.1 | — | — |
Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.
Strategy
Stated strategic themes (FY2025 10-K, Q3–Q4 FY2025 and Q1–Q2 FY2026 releases, paraphrased)
-
Complete the transition to an "innovative manufacturing solutions provider" in oligonucleotide manufacturing (former CEO Dilly, November 2025). Management judges the ECO Synthesis and ligase businesses mature enough to commit to their market potential.
-
Industrialize ECO Synthesis. Move from gram scale (10 g achieved) to kilogram-scale GMP production through the ECO GMP Manufacturing Center. Full production capability is targeted by end-2027. The facility's purpose is to supply siRNA for preclinical studies and Phase 1 trials.
-
Convert innovator relationships into multi-year agreements. The path is evaluation, then licensing fees, milestones and clinical supply, and finally commercial supply if drugs succeed (SVP Jimenez, Q4 FY2025 call). At March 2026 the pipeline was 55 opportunities across more than 40 companies.
-
Build a CDMO channel. Three evaluation agreements are in place (Bachem, Nitto Denko Avecia, Axolabs). The goal is at least one additional strategic CDMO partnership by end-2026.
-
Monetize technology through licensing. The company is seeking a licensing deal with a major pharma company in H2 2026.
-
Regulatory pathfinding. Engagement with the FDA Emerging Technologies team on product quality, stereoisomer control and comparability of ECO-derived siRNA, with a meeting with the agency expected in Q4 2026.
-
Differentiate through stereochemistry. StereoSelect℠ offers enzyme-driven phosphorothioate stereo-control, presented at TIDES US in May 2025 and May 2026. The first partnership was announced on 28 September 2026.
-
Harvest pharma biocatalysis. Support customer product launches, including two products after Phase 3 and one FDA approval in H1 FY2026. Shift the mix toward higher-margin products and let low-margin legacy sales run off.
Initiatives register (last 24 months)
| Date | Initiative | Type | Targets / status |
|---|---|---|---|
| Sep–Oct 2024 | Leadership build-out (CTO Moore, CFO Erbez, SVP IP, SVP Commercial) plus $31 million ATM raise | Organization / capital | Completed |
| 2024–2025 | ECO Synthesis Innovation Lab build-out at headquarters | Platform investment | Operating; first revenue contract Mar 2025 |
| 2,025 | ISO 9001 modernization of non-GMP enzyme production | Quality | Certified (reported in Q1 FY2026) |
| Mid-2025 to Q4 2025 | CDMO evaluation programme (Bachem, Nitto Denko Avecia, Axolabs) | Channel partnerships | Three signed against a goal of one |
| Oct 2025 | Merck $37.8 million agreement | Non-dilutive capital | Cash received FY2025 |
| Nov 2025 | Reorganization: CEO succession and 24% workforce reduction | Cost programme | $3.4 million restructuring charge. Run-rate opex down about 12% in H1 FY2026. Secondary analyses cite about 25% burn compression. |
| FY2025–FY2027 | ECO GMP Manufacturing Center | Capacity | Retrofit H2 2026; full production end-2027; costs included in runway guidance |
| May 2026 | TIDES US presentations: stereo-control, ligase performance, sustainability metrics vs. SPOS | Market development | Completed |
| Jul 2026 | $25 million equity raise | Capital | Runway extended to end-2028 |
| H2 2026 | Big-pharma licensing deal; additional CDMO strategic partnership; FDA meeting | Commercial / regulatory | Pending |
Guidance and medium-term targets
| Guidance item | Detail (as of Q2 FY2026, 11 Aug 2026) |
|---|---|
| FY2026 total revenue | $72–76 million (reiterated). Implies H2 FY2026 revenue of $41.8–45.8 million (computed) against H1 of $30.2 million. |
| FY2026 gross margin | High-60% range |
| Cash runway | Through end-2028, including GMP build-out (extended from end-2027 after the July 2026 raise) |
| Profitability | No explicit target currently. Earlier (2024) guidance targeted cash-flow-positive around end-2026; this was dropped with the ECO pivot. |
Products & Services
Core technology platform
CodeEvolver® protein engineering platform. This is the company's proprietary directed-evolution system. It combines gene-library diversification, high-throughput robotic screening, next-generation sequencing and machine-learning-guided design to evolve enzymes toward commercially specified performance targets, such as activity, selectivity, stability and solvent or temperature tolerance. It is monetized in two ways: internally, to develop products, and externally, through platform licences. Historical platform licensees have included GSK (2014), Merck (2015) and Novartis (2019). Target customers are large pharma with in-house process chemistry groups.
Pharma biocatalysis portfolio (small-molecule manufacturing)
| Offering | Description and capabilities | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|
| Custom commercial biocatalysts | Enzymes engineered for a specific API step, for example the transaminase used in Merck's sitagliptin process (2010 green chemistry award). Replace metal catalysts or multi-step chemistry, improve yield and reduce waste. | Innovator and generic pharma, CDMOs | Ongoing. Management cites support for about 14 commercial products (Q2 FY2026 call). | Per-kg enzyme supply under supply agreements, often with take-or-pay or supply-assurance features |
| CDX-616 (PAXLOVID™ enzyme) | Engineered enzyme used in Pfizer's nirmatrelvir manufacturing | Pfizer | Peak FY2022 ($75.4 million); negligible after FY2023 | Enzyme supply and fees (Pfizer fee deferral of $8.2 million released in FY2023) |
| Codex® Biocatalyst Panels and Kits | Off-the-shelf screening panels of enzyme classes (ketoreductases, transaminases, imine reductases and others) that let chemists identify starting enzymes | Process R&D chemists | Long-standing product line | Catalogue pricing per panel/kit (not disclosed) |
| Pharmaceutical intermediates | Sale of enzymatically produced intermediates | Pharma | Legacy; declining | Per-kg (not disclosed) |
| Technology transfer / supply assurance | Transfer of processes and enzyme-manufacturing know-how to the customer, or guaranteed supply | Merck (Oct 2025, $37.8 million) | Executed Q4 FY2025 | Lump-sum, recognised mainly as R&D revenue in Q4 FY2025, partly in Q1 FY2026 |
| Late-stage launch support | Process support for two pharma biocatalysis products after successful Phase 3 data. One customer product received FDA approval in H1 FY2026 (Q1 FY2026 release). | Pharma | 2026 launches | Product supply. Higher margin than legacy products per management. |
ECO Synthesis® Manufacturing Platform (oligonucleotides / RNAi)
| Offering | Description and capabilities | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|
| ECO Synthesis platform (fully enzymatic) | Enzymatic tools and processes for large-scale siRNA manufacture. Enzymes engineered via CodeEvolver for nucleotide addition and assembly. Aims to beat solid-phase oligonucleotide synthesis (SPOS) on purity, yield, solvent use and scalability. | RNAi drug innovators, CDMOs | Gram-scale shown in 2023; 10 g batch in FY2025; single-nucleotide initiation of enzymatic RNA synthesis shown in 2026 | Evaluation and feasibility fees; material supply; planned licensing fees, milestones and clinical/commercial supply agreements |
| dsRNA Ligase (chemoenzymatic) | Engineered ligase that joins shorter chemically made fragments into full-length siRNA duplexes, lowering cost and impurity burden versus full-length SPOS | Innovators and CDMOs running hybrid processes | Commercial. A customer made a 3 kg siRNA batch with it (FY2025). Data presented at TIDES USA 2025–2026. | Enzyme supply (per-gram/kg) |
| StereoSelect℠ technology | Enzyme-driven control of phosphorothioate stereochemistry in siRNA. Can deliver defined stereoisomer configurations that SPOS cannot practically achieve, with a potential potency and quality advantage. | Innovators pursuing next-generation siRNA | Data at TIDES US (May 2025 and May 2026). First partnership announced 28 Sep 2026. | Collaboration fees; potential licensing |
| ECO Synthesis Innovation Lab services | Non-GMP siRNA manufacture at headquarters for preclinical work, e.g. a low-seven-figure contract for 50 g of siRNA for a cardiovascular indication | Biotech innovators | First revenue-generating contract Mar 2025 | Fee-for-service |
| ECO GMP Manufacturing Center | Leased facility to be retrofitted for kilogram-scale GMP siRNA supply (preclinical, Phase 1, potentially Phase 2) | Innovators | Building-permit application in 2026; retrofit H2 2026; full production by end-2027 | Contract manufacturing (planned) |
| CDMO technology evaluations | Evaluation and integration agreements so CDMOs can adopt ECO at scale | Bachem, Nitto Denko Avecia, Axolabs | Signed 2025 | Evaluation fees; target is a strategic partnership by end-2026 |
Life-science tools and genomics enzymes (largely out-licensed)
| Offering | Description | Counterparty / status |
|---|---|---|
| Codex® HiCap RNA Polymerase | Engineered T7-type RNA polymerase for co-transcriptional mRNA capping, improving capping efficiency in mRNA manufacture | Exclusively licensed worldwide to Aldevron (Dec 2023): technical milestones, commercial milestones and royalties |
| Engineered dsDNA ligase | Ligase for NGS library preparation | Exclusive global licence to Roche (Feb 2024): upfront and technical milestones |
| Codex® HiFi DNA Polymerase | High-fidelity polymerase for PCR/NGS | Developed in the early 2020s |
| Engineered transposase | Transposase for genomics library preparation, developed with seqWell | Unveiled at AGBT (Feb 2024) |
Discontinued or divested biotherapeutics (for completeness)
| Asset | Indication | Status |
|---|---|---|
| CDX-7108 | Exocrine pancreatic insufficiency (oral enzyme) | Sold to Nestlé Health Science (Dec 2023): $5 million upfront, up to $15 million in development and $25 million in commercial milestones, single-digit royalty on net sales above a baseline. Option on amylase/protease assets worth $2.5 million plus $2.5 million. |
| CDX-6114 | Phenylketonuria | Discontinued under the 2023 refocus; Nestlé collaboration terminated |
| CDX-6512 | Homocystinuria (oral methionine-gamma-lyase) | Preclinical; discontinued |
| Takeda gene-therapy transgenes | Fabry and other lysosomal disorders | Collaboration wound down (historical) |
Financial Narrative
Income statement: notes and sources
Sources: FY2022 10-K and Q4 FY2022 release (FY2021–FY2022); FY2023 10-K (FY2023 revenue, product revenue, cost of product revenue, total costs); AP/Zacks earnings snapshot (FY2023 net loss of $76.2 million and EPS of -$1.12; FY2023 EPS should be cross-checked against the 10-K); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Gross profit and operating income for FY2021–FY2023 are computed.
Margins and growth
Revenue CAGR. FY2021–FY2025 (4 years): -9.5% (computed: 104.8 to 70.4). FY2020–FY2025 (5 years): +0.4% (computed: 69.1 to 70.4). The flat five-year CAGR conceals a full boom-bust cycle driven by PAXLOVID.
Commentary. The five-year record splits into three regimes.
The first regime is the PAXLOVID windfall (FY2021–FY2022). Revenue peaked at $138.6 million, of which $75.4 million came from enzyme sales tied to a single COVID antiviral. Even then the company lost money ($33.6 million in FY2022), because R&D was scaled up to $80.1 million to fund biotherapeutics and new platforms. This is the key analytical point: Codexis did not convert peak revenue into durable profitability or self-funded runway.
The second regime is the collapse and reset (FY2023–FY2024). Revenue halved in FY2023 as Pfizer demand disappeared. The net loss widened to $76.2 million, including asset impairments in Q4 FY2023. FY2024 revenue fell a further 15% to $59.3 million, and product gross margin compressed to 56% because of lower-margin legacy product mix.
The third regime is transition with mix improvement (FY2025–H1 FY2026). Revenue recovered 19% to $70.4 million, almost entirely because of the $37.8 million Merck agreement. Excluding that item, underlying revenue would have been well below FY2024 (rough computed estimate about $33–40 million, depending on how much of the $37.8 million was recognised in FY2025 versus Q1 FY2026). Product gross margin rose to 64% and then to 71–73% in Q1–Q2 FY2026 as newly launched customer products carried higher margins. Operating expenses fell from $117.9 million to $112.1 million despite higher R&D. The November 2025 reduction in force shows up in H1 FY2026 opex, which was down 12% year on year.
Balance sheet: notes and sources
Sources: FY2025 10-K Liquidity section (cash and short-term investments for FY2023–FY2025); Q4 FY2025 8-K balance sheet (FY2024–FY2025). The zero debt for FY2021–FY2023 reflects the absence of borrowings before the February 2024 Innovatus facility. Net debt excludes lease liabilities. Accumulated deficit was $606.8 million at FY2025.
Interim update (30 June 2026, Q2 FY2026 8-K). Cash and equivalents were $27.2 million and short-term investments $27.7 million, a total of $54.9 million. Total assets were $120.1 million and equity $33.0 million. Debt was $40.9 million: $7.1 million current and $33.8 million long-term. Adding the July 2026 offering's roughly $25 million of net proceeds gives management's stated pro forma cash of about $80 million.
Cash flow: notes and sources
Verified interim data points: net cash used in operating activities was $7.8 million in Q1 FY2024 and $9.2 million in Q1 FY2023 (Q1 FY2024 10-Q), and $22.8 million in H1 FY2026 (Q2 FY2026 10-Q, via secondary summary). Equity raised: about $31 million via ATM in Q3 FY2024; about $17.3 million via ATM in Q2 FY2025 (computed as $27.3 million total less the $10 million loan tranche); about $25 million net in July 2026.
Implied burn. Liquidity moved from $73.5 million (FY2024 year-end) to $78.2 million (FY2025 year-end). That increase came after about $27 million of external capital in 2025 and about $38 million of Merck cash, which implies an underlying FY2025 cash consumption of roughly $55–60 million before those inflows (computed, approximate). H1 FY2026 operating burn of $22.8 million annualizes to about $45 million, before GMP retrofit capex.
Ratios: notes and sources
All ratios are computed from reported balance sheet and income statement data. Innovatus loan effective interest rate is about 12.7% (secondary summary of the Q2 FY2026 10-Q).
Ratio commentary. Codexis's liquidity ratios look comfortable at about 4x current ratio, but that reflects balance-sheet cash funded by equity and debt rather than operating self-sufficiency. Leverage has risen materially. Debt/equity went from 0 before 2024 to 0.79x at FY2025 and about 1.24x at 30 June 2026 (computed: $40.9 million ÷ $33.0 million), before the July raise rebuilt equity. The Innovatus loan has a floating rate of prime plus 3.25% with a 7.50% floor and 2.0% paid-in-kind. It carries liquidity and net-product-revenue covenants. Covenant compliance is flagged as a risk factor in every 2025–2026 earnings release.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (USD Mn)
| Segment revenue (USD Mn) | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
Performance Enzymes | 48.1 | 90.5 | 126.6 | — |
Novel Biotherapeutics | 21.0 | 14.2 | 12.0 | — |
Total revenue | 69.1 | 104.8 | 138.6 | 70.1 |
Segment growth and mix (%)
| Segment growth and mix (%) | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
Performance Enzymes YoY growth | — | 88 | 40 |
Novel Biotherapeutics YoY growth | — | -32 | -16 |
Performance Enzymes share of total | 69.7 | 86.4 | 91.4 |
Novel Biotherapeutics share of total | 30.3 | 13.6 | 8.6 |
Business Area Details
| Business area | Contents | Revenue lines | FY2025 commentary |
|---|---|---|---|
Pharma biocatalysis (small molecule) | Custom engineered enzymes for API processes; Codex® panels and kits; CodeEvolver licences; technology transfers | Product revenue and R&D revenue | Includes the $37.8 million Merck agreement recognised mainly in Q4 FY2025. Supporting the commercial launch of two pharma biocatalysis products after successful Phase 3 data. |
ECO Synthesis Manufacturing Platform (oligonucleotides) | Enzymatic siRNA synthesis; dsRNA ligase (chemoenzymatic); StereoSelect℠ stereo-control; Innovation Lab manufacturing services; planned GMP Manufacturing Center | Product revenue (ligase, ECO enzymes) and R&D revenue (feasibility, evaluation, material supply) | 11 revenue-bearing contracts by Q3 FY2025. 55 opportunities across 40+ companies by Mar 2026. CDMO agreements with Bachem, Nitto Denko Avecia and Axolabs. |
Legacy / monetized assets | CDX-7108 (Nestlé), HiCap RNA polymerase (Aldevron), dsDNA ligase (Roche), transposase (seqWell), Codex HiFi DNA polymerase | Milestones and royalties (R&D revenue) | Contingent and back-ended |
Revenue by Segment
| Quarterly metric (USD Mn) | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 |
|---|---|---|---|---|---|---|---|---|
Product revenue | 11.2 | 9.8 | 6.1 | 7.4 | 6.8 | 5.8 | 7.2 | 13.2 |
R&D revenue | 1.7 | 11.6 | 1.5 | 7.9 | 1.8 | 33.1 | 8.1 | 1.7 |
Total revenue | 12.8 | 21.5 | 7.5 | 15.3 | 8.6 | 38.9 | 15.2 | 14.9 |
Net income (loss) | -20.6 | -10.4 | -20.7 | -13.3 | -19.6 | 9.6 | -8.7 | -12.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome statement (USD Mn)
| Income statement (USD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total revenue | 104.8 | 138.6 | 70.1 | 59.3 | 70.4 |
Cost of product revenue | 22.2 | 38.0 | 12.8 | 16.3 | 9.3 |
Gross profit (revenue less cost of product revenue) | 82.5 | 100.6 | 57.3 | 43.1 | 61.0 |
R&D expense | 55.9 | 80.1 | — | 46.3 | 52.3 |
SG&A expense | 49.3 | 52.2 | — | 55.1 | 47.1 |
Restructuring charges | 0.0 | 3.2 | — | 0.0 | 3.4 |
Total costs and operating expenses | 127.5 | 173.5 | 138.2 | 117.9 | 112.1 |
Operating income (loss) | -22.7 | -34.9 | -68.1 | -58.5 | -41.7 |
Pre-tax income (loss) | — | — | — | -65.2 | -43.9 |
Net income (loss) | -21.3 | -33.6 | -76.2 | -65.3 | -44.0 |
EPS basic and diluted (USD) | -0.33 | -0.51 | -1.12 | -0.89 | -0.50 |
Dividends per share (USD) | 0 | 0 | 0 | 0 | 0 |
Margin and growth metrics (%)
| Margin and growth metrics (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY | 51.7 | 32.3 | -49.4 | -15.4 | 18.6 |
Product gross margin (as reported) | 69 | 67 | 70 | 56 | 64 |
Gross margin on total revenue (computed) | 78.8 | 72.6 | 81.7 | 72.6 | 86.7 |
Operating margin (computed) | -21.7 | -25.2 | -97.1 | -98.6 | -59.3 |
Net margin (computed) | -20.3 | -24.2 | -108.7 | -110.0 | -62.5 |
R&D expense as % of revenue | 53.3 | 57.8 | — | 78.0 | 74.3 |
Balance Sheet
| Balance sheet (USD Mn, year-end) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | — | — | — | 149.0 | 147.8 |
Cash and cash equivalents | — | — | 65.1 | 19.3 | 50.8 |
Short-term investments | — | — | 0.0 | 54.2 | 27.4 |
Cash, equivalents and short-term investments | — | — | 65.1 | 73.5 | 78.2 |
Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Long-term debt | 0.0 | 0.0 | 0.0 | 28.9 | 40.1 |
Net debt (negative = net cash) | — | — | -65.1 | -44.6 | -38.1 |
Total stockholders' equity | — | — | — | 66.9 | 50.5 |
Goodwill | — | — | — | 2.5 | 2.5 |
Working capital (current assets less current liabilities) | — | — | — | 75.1 | 71.5 |
Operating lease liabilities (current plus long-term) | — | — | — | 31.0 | 33.1 |
Cash flow (USD Mn)
| Cash flow (USD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Debt drawn | 0 | 0 | 0 | 30.0 | 10.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 |
|---|---|---|
ROE (%, net income ÷ average equity; FY2024 on year-end equity) | -97.6 | -74.9 |
ROA (%, net income ÷ average assets; FY2024 on year-end assets) | -43.8 | -29.6 |
ROIC | Not meaningful (negative NOPAT) | Not meaningful |
Current ratio (x) | 4.18 | 3.82 |
Debt / equity (x) | 0.43 | 0.79 |
Net debt / EBITDA | Not meaningful (net cash; negative EBITDA) | Not meaningful |
Interest coverage (EBIT ÷ interest expense) | Negative | Negative |
Asset turnover (x, revenue ÷ year-end assets) | 0.40 | 0.48 |
Geographic revenue (USD Mn)
| Geographic revenue (USD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total | 70.1 | 59.3 | 70.4 |
Revenue driver (USD Mn)
| Revenue driver (USD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Product revenue | 42.9 | 36.8 | 26.0 |
R&D revenue | 27.2 | 22.6 | 44.4 |
Share price reference points (USD)
| Share price reference points (USD) | Value |
|---|---|
IPO price (22 Apr 2010) | 13.00 |
All-time high (8 Nov 2021) | 42.01 |
Close, 28 Feb 2024 | 3.74 |
Close, 23 Jul 2026 (pre-offering) | 1.99 |
July 2026 offering price | 1.50 |
Close, 9 Sep 2026 (latest verified) | 1.43 |
52-week low (as of Aug–Sep 2026) | 0.96 |
52-week high (as of Aug–Sep 2026) | 3.87 |
Performance Details
| Performance | Return |
|---|---|
1-year (to 9 Sep 2026) | About -42% (market-data aggregator) |
5-year | About -95% (computed: from about $30+ in autumn 2021 to about $1.4; approximate) |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalization | About USD 156M | Price × shares |
Enterprise value | About USD 117M | Market cap + debt of $40.9M − pro forma cash of about $80M |
EV / Sales (TTM to Q2 FY2026, revenue $77.7M) | About 1.5x | Computed |
EV / Sales (FY2026 guidance midpoint, $74M) | About 1.6x | Computed |
P/E | Not meaningful (loss-making) | — |
EV / EBITDA | Not meaningful (negative EBITDA) | — |
P/B | About 2.8x | Equity of $33.0M at 30 Jun 2026 plus about $25M raise |
Capital Markets
| Item | Detail |
|---|---|
Dividend policy | Has never paid a cash dividend; none expected |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Equity issuance history | ATM about $31M (Q3 2024); ATM about $17M (Q2 2025); underwritten offering about $25M net (Jul 2026) |
Warrants | 424,028 shares issued to Innovatus (Feb 2024) |
Debt maturity (USD Mn)
| Debt maturity (USD Mn) | FY2026 | FY2027 |
|---|---|---|
Innovatus term loan principal due (approximate) | 0.0 | 7.1 |
Analyst Conclusions
Guidance and expectations
Management guides FY2026 revenue of $72–76 million, gross margin in the high-60% range, and cash runway through end-2028 including the GMP build-out (Q2 FY2026 8-K). H1 FY2026 revenue of $30.2 million means H2 must deliver $41.8–45.8 million. On the Q2 call an analyst described this as a pretty significant step-up. It relies on a back-half-weighted mix of product launches, ECO contracts and, implicitly, licensing or milestone income.
Bull case
-
Margin and mix inflection. Product gross margin of 73% in Q2 FY2026, with product revenue up 79% year on year, shows the biocatalysis franchise can still grow as customers' new products launch. That provides a financial floor beneath the ECO option.
-
Platform validation by sophisticated counterparties. Merck ($37.8 million), three CDMOs, multiple innovators, a 3 kg ligase batch, and a StereoSelect partnership (September 2026) suggest ECO is moving from feasibility to procurement.
-
Asymmetric valuation. An EV of about $117 million is about 1.5x sales and only modestly above pro forma cash plus the value of the biocatalysis franchise. A single big-pharma licence (targeted for H2 2026) or a CDMO strategic deal could rerate the stock.
Bear case
-
Earnings quality and concentration. FY2025 "growth" was one Merck deal (about 51% of revenue). Without similar deals, underlying revenue has been shrinking since FY2022, and guidance depends on back-half events.
-
Capital intensity and dilution. About $45 million of annualized operating burn plus GMP capex and Innovatus amortization from 2027 imply further raises before ECO generates meaningful revenue. The July 2026 deal was priced at $1.50, and Nasdaq $1 compliance is a live risk.
-
Adoption and regulatory timeline. GMP capacity arrives only at end-2027 and is sized for preclinical and Phase 1 work. Commercial-scale ECO revenue likely depends on a CDMO partner and FDA acceptance, so it is probably a 2029+ event, which strains a runway that ends in 2028.
Catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| Oct–Nov 2026 | Q3 FY2026 results (an aggregator estimates mid-October; unconfirmed). Track how much of the $41.8–45.8 million H2 requirement is booked. |
| H2 2026 | Big-pharma licensing deal (company target) |
| By end-2026 | Additional strategic CDMO partnership (company target) |
| Q4 2026 | FDA Emerging Technologies meeting on ECO-derived siRNA |
| H2 2026 | GMP building permit and start of retrofit |
| Ongoing | Conversion of the pipeline (55 opportunities, 40+ companies) into multi-year agreements |
| Ongoing | Product gross margin holding in the high-60s to low-70s |
| Feb 2027 | End of the Innovatus interest-only period; covenant headroom |
| Ongoing | Share price vs. the $1.00 Nasdaq threshold |
| Mar 2027 | FY2026 10-K and FY2027 guidance |
Concluding analyst verdict
Codexis is a credible technology company with a poor financial track record. Its distinctive asset is not its income statement but its two-decade library of enzyme-engineering capability. That capability has twice proved it can change how drugs are made: in Merck's sitagliptin process and in Pfizer's PAXLOVID supply chain. The company is now trying to repeat the feat in oligonucleotide manufacturing, where the strategic logic is strong. If siRNA medicines reach mass-market cardiovascular populations, today's solid-phase chemistry will face real cost, capacity and sustainability limits. An enzymatic route offering stereochemical control that SPOS cannot match would address exactly those limits.
The evidence since early 2025 is encouraging on technology and channel: gram-to-kilogram scale points, three top-tier CDMO evaluations, paying innovator contracts and a first StereoSelect partnership. The legacy biocatalysis franchise is also showing a genuine margin upgrade.
The financial story remains the binding constraint. Five consecutive annual losses total more than $240 million. One customer supplies about half of revenue. Debt now costs about 12.7%, and the latest equity was issued at $1.50. Management's runway to end-2028 is credible on paper, but it assumes back-half revenue delivery and contingent deals, and the commercial-scale payoff from ECO probably sits beyond that horizon. The leadership change to a manufacturing-operations CEO fits the task, but the company has pivoted three times in fifteen years, and investors will want proof before giving credit.
On balance, CDXS is a high-risk, high-optionality micro-cap. It should be monitored on a short list of hard catalysts: a named big-pharma licence, a CDMO strategic partnership, constructive FDA feedback, and H2 FY2026 revenue landing within the $72–76 million guidance. Positive delivery on two or more could justify a material re-rating from about 1.5x EV/Sales. Misses would likely force another dilutive financing and test the Nasdaq listing threshold. The stance is speculative and catalyst-driven; position sizing should reflect a binary outcome distribution.
End of dossier. All figures are in USD unless otherwise stated. Where sources conflict, the conflict is noted in place: for example, the Merck agreement is described as a "Supply Assurance Agreement" in the November 2025 release and a "Technology Transfer Agreement" in the March 2026 release; liquidity was "$78.2M cash, cash equivalents and short-term investments" vs. "$50.8M cash and cash equivalents" at FY2025; and FY2023 EPS was -$1.12 per AP/Zacks, which should be confirmed against the FY2023 10-K.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Age | Prior roles | Education |
|---|---|---|---|---|---|
Alison Moore, Ph.D. | President and CEO; Director (Class III, term to 2028) | CEO since 7 Nov 2025. Chief Technical Officer Sep 2024–Nov 2025. Director Jun 2020–Sep 2024; re-appointed Nov 2025. | 59 | Chief Technical Officer, Allogene Therapeutics (2018–2023); SVP Process Development, Amgen (2013–2018), plus earlier Amgen operations roles including VP Site Operations, Fremont; Director of CMC and Regulatory, Genentech (2005–2006). Director of Artiva Biotherapeutics. | B.Sc. Pharmacology (Hons) and Ph.D. Cell Biology, University of Manchester |
Georgia Erbez | CFO (since Sep 2024) and Chief Business Officer (since Nov 2025) | 2 years | 59 | COO, Walking Fish Therapeutics; CFO, Harpoon Therapeutics (2018–2022); CBO/CFO, Zosano; CFO, Revolution Medicines, Asterias, Raptor; investment banking at Cowen and Jefferies. Director of Coherus BioSciences. | B.A. International Relations (Economics), UC Davis |
Stefan Lutz, Ph.D. | Chief Scientific Officer (since Nov 2025) | At Codexis since May 2020 (SVP Research) | 56 | Faculty, Emory University (2002–2020) | Ph.D. Chemistry, University of Florida; M.S. Biotechnology, Teesside; B.S. Chemical Engineering, FH Winterthur |
Britton Jimenez | SVP, Sales and Marketing (leads commercial) | Joined 2024 | — | Not detailed in sources reviewed | — |
John Schiffhauer | SVP, Intellectual Property | Since Oct 2024 | — | Not detailed in sources reviewed | — |
Directors' Remuneration
| NEO (USD) | Salary | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
Alison Moore (CEO) | 524,732 | 255,994 | 1,065,223 | 463,125 | 14,205 | 2,323,279 |
Georgia Erbez (CFO/CBO) | 507,423 | 117,444 | 487,523 | 237,500 | 1,040 | 1,350,930 |
Stefan Lutz (CSO) | 481,572 | 76,475 | 317,457 | 232,750 | 14,840 | 1,123,094 |
Stephen Dilly (Exec. Chair, former CEO) | 758,903 | 374,954 | 489,686 | 521,051 | 50,007 | 2,194,601 |
Kevin Norrett (former COO) | 501,298 | 57,306 | 10,582 | 250,000 | 514,720 | 1,333,906 |
Board of Directors
| Director | Role | Since | Age | Class / term | Committees | Background |
|---|---|---|---|---|---|---|
Stephen G. Dilly, M.B.B.S., Ph.D. | Executive Chair (not independent) | 2020 | 66 | I / 2029 | — | CEO Codexis 2022–2025; CEO Sierra Oncology (sold to GSK 2022); CEO Aimmune (2014–2018); Genentech, Chiron, SmithKline Beecham. Now also CEO and Chair of Sonoma Biotherapeutics (since Nov/Dec 2025). |
Alison Moore, Ph.D. | President and CEO (not independent) | 2025 (also 2020–2024) | 59 | III / 2028 | — | See above |
David V. Smith | Lead Independent Director | 2016 | 66 | III / 2028 | Audit (Chair), Compensation, Strategy, Nominating/Governance | Former CFO of Five Prime, Thoratec and Chiron. Audit committee financial expert. |
Raymond De Vré, Ph.D. | Independent | 2024 | 58 | I / 2029 | Audit, Science and Technology | Former CEO, PolyPeptide Group (peptide/oligo CDMO); Dr. Reddy's; McKinsey partner |
Rahul Singhvi, Sc.D. | Independent | 2022 | 61 | I / 2029 | Science and Technology | CEO, Axella Biosciences; former CEO, National Resilience and Novavax; Takeda vaccines COO. Also on the Strategic Advisory Board ($25,000 a year). |
Cynthia Collins | Independent | 2025 | 68 | II / 2027 | Compensation (Chair since Feb 2026) | Former CEO, Editas Medicine; interim CEO, Nutcracker Therapeutics; GE Healthcare cell therapy |
H. Stewart Parker | Independent | 2022 | 70 | II / 2027 | Audit, Strategy (Chair), Nominating/Governance | Founder and former CEO, Targeted Genetics; director of Sangamo |
Christos Richards | Independent | 2025 | 68 | II / 2027 | Nominating/Governance (Chair) | Global Head of Healthcare, Calibre One (executive search) |
Esther Martinborough, Ph.D. | Independent | 2021 | 60 | III / 2028 (reclassified 10 Apr 2026) | Science and Technology (Chair), Compensation, Strategy | Former CSO, Escient (acquired by Incyte) |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Aberdeen Group plc | 7,966,498 | 8.8 |
Opaleye Management Inc. | 6,789,738 | 7.5 |
BlackRock, Inc. | 5,979,480 | 6.6 |
Integrated Core Strategies (US) LLC (Millennium) | 4,734,627 | 5.2 |
All directors and executive officers (11 persons) | 3,224,869 | 3.5 |
— of which Stephen Dilly (includes 1.82 million options) | 2,435,802 | 2.6 |
Competitive Landscape
Key Competitors
| Competitor | Type | Relative positioning vs. Codexis |
|---|---|---|
Novonesis (Novozymes plus Chr. Hansen) | Global industrial enzyme leader | Far larger scale, focused on industrial and food enzymes; less custom pharma biocatalysis |
dsm-firmenich | Diversified life sciences; historical pharma biocatalysis | Scale and fermentation; less focused on directed evolution for pharma |
Almac Group (Selcia/Almac Sciences biocatalysis) | Private CDMO with enzyme engineering | Integrated with CDMO services; direct competitor for custom pharma enzymes |
Enzymaster (Ningbo) | Chinese biocatalysis specialist | Low-cost competitor in pharma enzymes, especially generics |
c-LEcta (Kerry Group) | Enzyme engineering and fermentation | Competes in pharma and food enzymes |
Prozomix | UK enzyme panel supplier | Competes with Codex® panels and kits |
EnzymeWorks | Chinese enzyme supplier | Price competitor; historical litigation counterparty |
In-house pharma groups (Merck, Pfizer, GSK, Novartis) | Internal capability, often built on licensed CodeEvolver | Customers become competitors once a platform is licensed |
Agilent Technologies (nucleic acid solutions) | Incumbent SPOS API manufacturer | Massive installed SPOS capacity |
Nitto Denko Avecia | Oligo CDMO (SPOS) | Simultaneously a partner (evaluation) and incumbent |
Bachem | Peptide/oligo CDMO | Partner and incumbent; scaling oligo capacity |
Hongene Biotech / WuXi STA / ST Pharm | Asian oligo CDMOs and monomer suppliers | Low-cost SPOS capacity; potential ECO adopters |
Thermo Fisher Scientific | Phosphoramidites and oligo services | Upstream incumbent whose reagents ECO could displace |
EnPlusOne Bio | Enzymatic RNA synthesis start-up | Direct technology competitor in enzymatic RNA synthesis |
Ansa Biotechnologies / DNA Script / Molecular Assemblies | Enzymatic DNA synthesis | Adjacent (DNA); signals capital flowing into enzymatic synthesis |
Ligation-chemistry developers (innovators' in-house; e.g. Novartis/Alnylam process groups) | In-house chemoenzymatic/ligation processes | Could bypass Codexis's ligase |
Competitor Detail
| Benchmark (FY2025 unless stated) | Codexis |
|---|---|
Revenue | USD 70.4M |
Revenue growth | +18.6% (Merck-aided) |
Operating margin | -59.3% |
R&D intensity | 74.3% |
